Navigation Links
DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
Date:2/2/2010

CLEVELAND, Feb. 2 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the 13th Annual DIA Workshop in Japan for Clinical Data Management.  Laurence Birch, Chairman of the Board, and Bill Coates, Vice President of Sales, will participate in the workshop with DATATRAK's strategic partner, NTT DATA Corporation.  The event takes place on February 4th and 5th in Tokyo, Japan.

About DIA Japan.

Held at the Tower Hall Funabori, this Drug Information Association international meeting for specialists focuses on the approaches to policy and strategic issues for Japanese Clinical Data Management activities.  For more information on the 13th Annual DIA Workshop in Japan for Clinical Data Management, please see http://www.diahome.org.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK International, Inc. Announces Year-End Backlog
2. DATATRAK Signs Five-Year Registry Study
3. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
4. PFC Pharma Joins DATATRAKs CRO Connect Program
5. DATATRAK Signs 6 Year Study with New Device Client
6. DATATRAK to Present at 2009 SCDM Annual Conference
7. DATATRAK eClinical(TM) Supports Multifaceted Studies
8. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
9. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
10. DATATRAK International Reports First Quarter Results for 2008
11. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PUNE, India , January 24, 2017 /PRNewswire/ ... Market Research, titled, "Cold Chain Logistics Market by Application ... Frozen Dessert, Meat, Fish & Sea Food, Drugs & ... Forecasts, 2014-2022," projects that the global cold chain logistics ... growing at a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... 2017 , ... Inspiration, Community & Mentorship – Top Students ... Fordham Institute’s High Stakes for High Achievers offer recommendations for how ... high-achieving students as a subgroup and reporting their results separately. Top students and ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... Scottsdale, AZ (PRWEB) , ... January 24, 2017 , ... ... than 30 lives in the last month. Yellow fever is primarily spread through contact ... the health community’s focus on how to prevent its spread. , According to multiple ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common ... Publishing authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, ...
Breaking Medicine News(10 mins):